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JOINT REGRESSION MODELING OF TWO CUMULATIVE INCIDENCE
FUNCTIONS UNDER AN ADDITIVITY CONSTRAINT
AND
STATISTICAL ANALYSES OF PILL-MONITORING DATA
Martin P. Houze, PhD
University of Pittsburgh, 2015
In the first part of this dissertation, we propose a parametric regression model for cumu-
lative incidence functions (CIFs) which are commonly used for competing risks data. Our
parametric model adopts several parametric functions as baseline CIFs and a proportional
hazard or a generalized odds rate model for covariate effects. This parametric model ex-
plicitly takes into account the additivity constraint that a subject should eventually fail
from one of the causes so the asymptotes of the CIFs should add up to one. Our primary
goal is to propose a parametric regression model that provides regression parameters for the
CIFs of both the primary and secondary risks. Moreover, we introduce a modified Weibull
baseline distribution. The inference procedure is straightforward. Parameters are estimated
via the maximization of the likelihood. Standard errors are obtained via the Hessian of the
log-likelihood. We demonstrate the good practical performance of this parametric model.
We simulate the underlying processes for cause 1 and cause 2, and compare our models with
some existing methods.
In the second part of this dissertation, we propose several approaches for the modeling and
analysis of medication bottle opening events data, and focus on frailty models, in both
parametric and semiparametric forms. This approach provides regression coefficients which
iv
are of great interest to investigators and clinicians. A time effect can also be estimated. We
apply our approaches to the analysis of a medication bottle opening events data set. To our
knowledge, this is the first study of prescription bottle opening events which focuses on time
between medication administrations through frailty models. We discuss the interpretation
of the random effect of a subject, and how it can help characterize the adherence of that
individual relative to that of the other subjects. We then present an exploratory cluster
analysis of the survival curves of the participants.
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1.0 JOINT REGRESSION MODELING OF TWO CUMULATIVE
INCIDENCE FUNCTIONS UNDER AN ADDITIVITY CONSTRAINT
1.1 INTRODUCTION
Cox regression models (Cox, 1972b) and accelerated failure time models (Wei et al., 1990; Jin
et al., 2003) are commonly used to analyze covariate effects on a single variable measuring
the time to an event. In many survival studies, there are several competing causes of failure.
The primary event, or the event of interest, may not be observed if the other competing
events occur first. For example, in the breast cancer study considered by Shi et al. (2013),
the primary event is the recurrence of a cancer growing locally. But this primary event may
be unobservable, or competing-risk censored, if the other events such as death or distant
metastasis have occurred first. In many other studies, investigators are interested in analyz-
ing the time to death due to a certain disease of interest. However some of the participants
will die from causes other than the disease of interest, for instance other diseases or trauma.
Hence it is of interest to take the cause of death into account and carry out cause-specific
analyses.
In a competing risks setting, some standard quantities such as the survival function may
not be well defined if removal of competing events is not conceptually realistic (Gooley et al.,
1999). Instead, the cumulative incidence function (CIF) has been an established quantity
to describe cumulative risks of an event of interest over time (Kalbfleisch and Prentice,
2002). The limit of a CIF is less than one, and is thus often referred to as subdistribu-
tion. Another approach in competing risks studies with covariates involves modeling the
cause-specific hazard functions via a proportional hazards assumption (Prentice et al., 1978;
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Beyersmann et al., 2012). Unfortunately, the cause-specific hazard function does not have a
direct interpretation in terms of survival probabilities for the particular failure type (Pepe,
1991; Gaynor et al., 1993). Many clinicians prefer using the CIF because it is intuitively
appealing and more easily understood by the nonstatistician.
Shi et al. (2013) point out that all subdistributions, or CIFs, should add up to one when
time goes to infinity, as one subject should eventually die from one of the competing causes.
Shi et al. (2013) also note that such additivity constraint is ignored in some commonly used
regression models for CIFs, such as the semi-parametric models of Fine and Gray (1999)
and Scheike et al. (2008), which only consider one event at a time. If several causes are of
interest, one may run their models several times (one iteration for each cause). However, it is
not clear how to interpret the sets of regression parameters when the CIFs do not add up to
one as time goes to infinity (Shi et al., 2013). Jeong and Fine (2007) presented a parametric
model based on CIFs, but did not seem to account for the constraint either.
We consider two causes K = 1, 2, one for the event of interest, and the other for the
competing event. Let T and C be the event time and censoring time. Let t denote time, and
z the covariates. Shi et al. (2013) presented a parametric model for simultaneous inference
of two CIFs. Their model adopts a modified logistic model as the baseline CIF and a
generalized odds-rate model for covariate effects. Moreover, it explicitly takes into account
the additivity constraint that a subject should eventually fail from one of the causes, so that
the asymptotes of the CIFs should add up to one,
P (K = 1|z) + P (K = 2|z) = 1. (1.1.1)
However Shi et al. (2013) did not explicitly model the covariate effects on the competing
cause. Rather, they specified the covariate effects on the competing cause indirectly through
the covariate effects on the primary cause and the additivity constraint.
Our primary goal is to propose a parametric regression model that is based on the frame-
work of Jeong and Fine (2007) and Shi et al. (2013), but provides regression parameters for
the CIFs of both the primary and secondary risks. Our model also accounts for the afore-
mentioned additivity constraint (1.1.1). Moreover, we update the model of Shi et al. (2013)
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by introducing a new baseline function: the modified Weibull CIF. The Weibull distribution
has been widely used in industrial and biomedical applications (Klein and Moeschberger,
2003), and is especially useful in modeling time to appearance of tumors in humans (Doll,
1971). However it cannot be directly used to model time to local cancer recurrence in our
breast cancer application, because of competing-risk censoring. We hence introduce an extra
leveling-off parameter in the modified Weibull CIF. The modified Weibull CIF can take a
range of shapes with one or two bendpoints. Some Weibull CIF curves are of concave in-
creasing shape, other curves are of sigmoidal shape, similar to the modified logistic function
(Cheng, 2009).
The rest of the document is organized as follows. We introduce our parametric models
in Section 1.2. Extensive simulation studies are performed in Section 1.3 to compare the
performance of our parametric model with the Fine and Gray (1999) method, the semipara-
metric model by Scheike et al. (2008) and the parametric model in Jeong and Fine (2007).
We applied all these regression models to the datasets of a breast cancer study in section
1.4.
1.2 MODEL FORMULATION
Let C be the censoring time, T be the time to an event, and K = 1, 2 be the cause indicator.
We observe Y = min(T,C) and η = KI{T < C}, where I is the indicator function. Let Zk
be a covariate vector with respect to the cause k event, k = 1, 2. Fine and Gray (1999) and
Fine (2001) assume that
gk{Fk(t; βk, Z)} = gk{F0k(t)}+ βkZ, (1.2.1)
where gk is some nondecreasing known function, and F0k(t) = Fk(t;Z = 0) is an invertible
and monotonically increasing function. The commonly used Fine and Gray method considers
g(u) = log{− log(1− u)}, (1.2.2)
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which gives a proportional hazards interpretation for subdistribution hazards.
In the current work, we will continue to adopt parametric forms for gk and F0k in (1.2.1)
as in Shi et al. (2013), and further improve the flexibility of the model by allowing covariate
effects on both causes 1 and 2 events. The parametric model is a convenient choice by
explicitly taking into account the additivity constraint. We will consider two families of
distributions for F0k, and focus on the commonly used transformation model (1.2.2). We
will also study a more general family of transformation models, the generalized odds rate
models,
log[{(1− u)−α − 1}/α], (1.2.3)
which include (1.2.2) as a special case.
Let fk(t;αk, βk, ψk, z) = F˙k(t;αk, βk, ψk, z), k = 1, 2, where the dot superscript denotes
a derivative with respect to t. Similar to Jeong and Fine (2007), we consider the following
full likelihood function
L =
n∏
i=1
[{ 2∏
k=1
fk(yi;αk, βk, ψk, zi)
I{Ki=k}
}{
1−
2∑
k=1
Fk(yi;αk, βk, ψk, zi)
}I{Ki=0}]
. (1.2.4)
Taking the first derivative of logL with respect to the parameters αk, βk, ψk, the max-
imum likelihood estimators (MLEs) α̂k, β̂k, ψ̂k may be determined using a numerical algo-
rithm, such as the Newton-Raphson method. The MLE of the cumulative incidence function
is then Fk(t, α̂k, β̂k, ψ̂k), by using the functional invariance property of the MLEs.
We assume certain regularity conditions for the MLEs, including consistency and asymp-
totic normality. Thus the observed information matrix can be derived by taking the sec-
ond derivatives of the log the likelihood function with respect to αk, βk, ψk. Letting θk =
(αk, βk, ψk), and applying the delta method, we can find the variance of Fk(t, θ̂, β̂k, ψ̂k) by
evaluating the expression
V̂ar
(
Fk(t, θ̂k)
)
=
(
∂Fk(t, θk)
∂θk
) ∣∣∣∣
θk=θ̂k
V̂ar
(
θ̂k
)(∂Fk(t, θk)
∂θk
)T ∣∣∣∣
θk=θ̂k
.
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Because θk = (αk, βk, ψk),
∂Fk(t,θ̂k)
∂θk
is equivalent to(
∂Fk(t, θk)
∂αk
,
∂Fk(t, θk)
∂βk
,
∂Fk(t, θk)
∂ψk
)
.
1.2.1 Modified logistic baseline with PH link function
Cheng (2009) proposed a modified three-parameter logistic distribution which models the
“leveling-off”of the cumulative incidence using an added parameter, making it more appro-
priate for survival data with competing risks. The modified logistic model accommodates
CIF curves of concave increasing shape or sigmoidal shape.
We now model cause 1 observations through the CIF of cause 1, P (T ≤ t,K = 1|z),
following the modeling in Shi et al. (2013), expressed as:
P (T ≤ t,K = 1|Z = 0) = F01(t; b1, c1, p1) = p1 exp{b1(t− c1)} − p1 exp(−b1c1)
1 + exp{b1(t− c1)} , (1.2.5)
where the parameter p1 corresponds to the long-term probability of the cause 1 event, b1
describes how fast the CIF approaches its asymptote p1, and c1 describes the “center” of
the rising. As demonstrated in Cheng (2009), the modified three-parameter logistic model
is a flexible function that characterizes the CIF. In contrast to the Gompertz model used in
Jeong and Fine (2006, 2007), the model in (1.2.5) is especially useful to capture CIFs that
have a sigmoidal shape.
Similar to Fine and Gray (1999) and Fine (2001), we also assume model (1.2.1) and
adopt g(u) = log{− log(1− u)}. Hence we obtain the CIF conditional on the covariates:
P (T ≤ t,K = 1|Z = z) = 1−
[
1− p1 exp{b1(t− c1)} − exp(−b1c1)
1 + exp{b1(t− c1)}
]exp(β1z)
. (1.2.6)
The same model was also considered in Shi et al. (2013) for the cause 1 event, and on the other
hand for the cause 2 event, the effects of covariates were only allowed indirectly through the
additivity constraint on the asymptotes. To address this limitation and to explicitly model
the covariate effects on the competing event while respecting the additivity constraint, we
propose to model the cause 2 CIF, P (T ≤ t,K = 2|z), through the conditional distribution
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P (T ≤ t|K = 2, z). That is,
P (T ≤ t,K = 2|z) = P (T ≤ t|K = 2, z)×P (K = 2|z) = P (T ≤ t|K = 2, z)×p2(z), (1.2.7)
where p2(z) is set by the constraint P (K = 1|z) + P (K = 2|z) = 1.
Note that P (T ≤ t|K = 2, z) is a proper conditional distribution which approaches 1 as
time goes to∞. Hence, we can use any of the existing parametric regression models for sur-
vival data, such as linear models for log time or the transformation models similar to (1.2.1)
except now the distributions are proper. Meanwhile, the modified logistic function can be
easily adapted to accommodate proper distribution functions by dropping the “leveling-off”
parameter, yielding the modified logistic function for the baseline conditional distribution:
P (T ≤ t|K = 2,Z = 0) = CDF02(t) = exp{b2(t− c2)} − exp(−b2c2)
1 + exp{b2(t− c2)} . (1.2.8)
If we again choose the log-log link function g(u) = log{− log(1− u)}, we have
P (T ≤ t|K = 2, z) = CDF2(t) = 1−
[
1− exp{b2(t− c2)} − exp(−b2c2)
1 + exp{b2(t− c2)}
]exp(β2z)
. (1.2.9)
We now use (1.2.7) and the additivity constraint in order to find p2(z). Due to the
additivity constraint for the baseline CIFs, F01(∞) + F02(∞) = 1, p2(z = 0) = 1 − p1. For
any given covariates z, again by the additivity constraint F1(∞, z) + F2(∞, z) = 1, we have
1− (1− p1)exp(β1z) + (1− (0)exp(β2z))× p2(z) = 1− (1− p1)exp(β1z) + p2(z) = 1,
and thus p2(z) = (1 − p1)exp(β1z). Coupled with the conditional model in (1.2.9), we can
explicitly model the covariate effects on the cause 2 CIF F2(t) as
P (T ≤ t,K = 2|z) = (1− p1)exp(β1z) ×
{
1−
[
1− exp{b2(t− c2)} − exp(−b2c2)
1 + exp{b2(t− c2)}
]exp(β2z)}
.
1.2.2 Modified Weibull baseline with PH link function
As we have discussed in the introduction, we also consider a modified Weibull distribution for
baseline CIFs, in addition to the modified logistic function. The Weibull distribution is used
extensively in applications to model survival times (Klein and Moeschberger, 2003), since
6
the Weibull curves can have one, or two bend points. We modify the Weibull distribution
to describe the baseline cause 1 CIF:
F01(t; k1, λ1, p1) = P (T ≤ t,K = 1|Z = 0) = p1{1− e−(t/λ1)k1}, (1.2.10)
where k1 > 0 is the shape parameter, λ1 > 0 is the scale parameter of the distribution, and
p1 controls the asymptote of the CIF.
Using the modified Weibull baseline CIF and the log-log link function in (1.2.1), we
obtain the CIF conditional on the covariates:
P (T ≤ t,K = 1|Z = z) = 1− (1− p1[1− exp{−(t/λ1)k1}])exp(β1.z).
We then turn to the modeling of cause 2 data following the strategy in (1.2.7). We start
by defining the cause 2 conditional distribution at baseline as
P (T ≤ t|K = 2,Z = 0) = CDF02(t) = 1− e−(t/λ2)k2 . (1.2.11)
If we again choose the log-log link function g(u) = log{− log(1− u)}, we obtain
P (T ≤ t|K = 2, z) = 1− {e−(t/λ2)k2}exp(β2.z).
Similarly to the previous model, the additivity constraint F01(∞) + F02(∞) = 1 results in
p2(z) = (1− p1)exp(β1.z). Therefore, the cause 2 conditional CIF F2(t) is given below:
P (T ≤ t,K = 2|z) = (1− p1)exp(β1.z) × {1− [e−(t/λ2)k2 ]exp(β2.z)}.
1.2.3 Modified logistic baseline with GOR link function
The above two modeling strategies were derived based on the log-log link function which is
equivalent to the proportional subdistribution hazard assumption for the cause 1 CIF, and
the proportional hazard assumption for the conditional distribution given the competing
event being the cause of failure. These assumptions may not be realistic in some applications.
Hence we consider a more general transformation function in (1.2.3), which includes the log-
log link as a special case.
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We begin the modeling of cause 1 observations with the same baseline modified logistic
CIF F01(t) as in (1.2.5). The generalized odds rate link has inverse function g
−1
1 (u) =
1− {α1 exp(u) + 1}−1/α1 . Then we have
P (T ≤ t,K = 1|z) = g−11 [g1{F01(t)}+ β1z].
We now turn to the modeling of the secondary risk quantities. Similarly as before, we
consider the baseline conditional distribution in (1.2.8).
We want to bring covariate effects into our modeling. We use link function g2(u) =
log[{(1 − u)−α2 − 1}/α2], which has inverse function g−12 (u) = 1 − (α2 × exp(u) + 1)−1/α2 ,
and obtain:
P (T ≤ t|K = 2, z) = CDF2(t) = g−12 [g2(CDF02) + β2z].
We now write out F1(∞):
F01(∞) = 1− {α1 × exp(log[{(1− p1)−α1 − 1}/α1] + β1z) + 1}−1/α1 .
Shifting to cause 2 CIF, we have F2(∞, z) = p2(z)× P (T ≤ ∞|K = 2, z) = p2(z).
Therefore the covariate-adjusted additivity constraint F1(∞, z)+p2(z)×CDF2(∞, z) = 1
results in p2(z) = 1− F1(∞, z).
Hence we have the following expression for p2(z) = {α1 × exp(log[{(1 − p1)−α1 − 1}/α1] +
β1z) + 1}−1/α1 .
Using the expression of p2(z) obtained from the covariate-adjusted additivity constraint,
we can write out the cause 2 CIF F2(t) as
P (T ≤ t,K = 2|z) ={α1 × exp(log[{(1− p1)−α1 − 1}/α1] + β1z) + 1}−1/α1
× g−12 (g2(CDF02) + β2z)).
That is, we explicitly model the covariate effects on the competing cause.
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1.2.4 Modified Weibull baseline with GOR link function
We begin the modeling of cause 1 observations with the same baseline CIF as in (1.2.10),
and for cause 2 data we use the baseline Weibull CDF as in (1.2.11).
We now need to incorporate covariate effects in the modeling of the secondary risk data.
To do so, we use link function g2(u) = log[{(1− u)−α2 − 1}/α2], which has inverse function
g−12 (u) = 1− (α2 × exp(u) + 1)−1/α2 , and obtain:
P (T ≤ t|K = 2, z) = g−12 [g2(CDF02) + β2z],
where CDF02 = P (T ≤ t|K = 2,Z = 0) = {1− e−(t/λ2)k2}.
We now compute F1(∞).
F1(∞) = 1− {α1 ∗ exp(log[{(1− p1)−α1 − 1}/α1] + β1z) + 1}−1/α1 .
Shifting to cause 2 CIF, and using the same additivity constraint as in the previous
model, we obtain p2(z) = {α1 × exp(log[{(1− p1)−α1 − 1}/α1] + β1z) + 1}−1/α1 .
Using p2 = 1−p1 which we obtained from the baseline CIF additivity constraint, we can
write out the baseline cause 2 CIF, denoted F02, as follows
P (T ≤ t,K = 2|z = 0) = (1− p1)(1− e−(t/λ2)k2 ).
Using the expression of p2(z) obtained from the covariate-adjusted additivity constraint,
we can write out the cause 2 CIF F2(t) and explicitly model the covariate effects on the
competing cause:
P (T ≤ t,K = 2|z) ={α1 × exp(log[{(1− p1)−α1 − 1}/α1] + β1z) + 1}−1/α1
× g−12 (g2[1− e−(t/λ2)
k2 ] + β2z)).
Some datasets may require a flexible model. The baseline CIF functions for cause 1 and
cause 2 do not have to be from the same parametric family. For instance, the modified
Weibull baseline function can be chosen for cause 1 events, while the modified logistic can be
chosen for cause 2 events. Furthermore, the regression can utilize the proportional hazards
approach for cause 1 data, and the generalized odds rate approach for cause 2 data.
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1.3 SIMULATIONS
We perform extensive simulation studies to evaluate the finite-sample performance of our
parametric regression models using the modified logistic function (LOG), and the modified
Weibull function (WEI) as compared to the Fine and Gray method (FG) and the time-
varying coefficients model proposed by Scheike et al. (Sch). Several scenarios are considered.
We let the baseline CIFs satisfy either a modified logistic function (LOG), or a Weibull
(WEI) function. The covariate effects follow a proportional hazard model for hazards of
sub-distribution (PH). Below we give details on how we simulate the data with the LOG
baseline and PH effects (LOG+PH). We assume that the baseline CIF for the primary cause
follows (1.2.5) with k = 1. The regression model on the cause 1 CIF satisfies g{F1(t; z)} =
g{F01(t)} + β1z, where z1 and z2 are drawn from the standard normal distribution and
g(u) = log{− log(1 − u)}. Then the cause 1 CIF conditional on the covariates z′ = (z1, z2)
has the form of (1.2.6) and β
′
1 = (β11, β12). Therefore, we simulate the event time by
F−11 (U ; z), where U ∼ uniform(0, 1) and F−11 is the inverse function of F1(t; z). Note that
F1 is improper and may not be invertible. When U < 1 − (1 − p1)exp(β′1z), we simulate the
event time by
T = F−11 (U ; z) = c1 +
1
b1
log
{
1− (1− U)exp(−β′1z) + p1 exp{−b1c1}
p1 − 1 + (1− U)exp(−β′1z)
}
,
with K = 1. When U ≥ 1 − (1 − p1)exp(β′1z), K = 2 and the event time T comes from the
cause 2 event.
As mentioned in Section 1.2, one needs to keep the additivity constraint (1.1.1). Thus,
for the competing cause (K = 2), the conditional distribution of T given K = 2 is
F (t|K = 2, z) = P (T ≤ t|K = 2, z) = 1− [1− exp{b2 × (t− c2)} − exp(−b2 × c2)
1 + exp{b2 × (t− c2)}
]exp(β2.z).
Then we simulate the event time T by F−1(V |K = 2, z), where F−1 is the inverse func-
tion of F and V ∼uniform(0,1). We also simulate independent censoring time C follow-
ing uniform(a, b), where a and b are constants greater than zero. The observable time is
Y = min(T,C) and the corresponding cause indicator is η = KI{T < C}. Different values
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of a and b are used and the percentage of censoring is around 15-25% for all our simulations.
In each run of our simulations, we generate 300 pairs of event times and associated cause
indicators. Next, we fit the simulated data by using our proposed parametric model with
the modified logistic (LOG) baseline and the PH transformation, and the modified Weibull
(WEI) and the PH transformation.
For the parametric models, the regression coefficient estimates are obtained by using the
R function “nlminb” to minimize the minus likelihood function (1.2.4). nlminb() performs
optimization subject to box constraints (i.e. upper and/or lower constraints on individual
elements of the parameter vector). The variance of the estimator is estimated via the inverse
of the Information matrix. The Information matrix is the negative of the expected value of
the Hessian matrix, the matrix of second derivatives of the likelihood with respect to the
parameters. The inverse is calculated via the R function “solve.” For the semi-parametric
models, we use the R function “crr” in the package cmprsk (Fine and Gray, 1999) and the
R function “comp.risk” in the package timereg (Scheike et al., 2008; Scheike and Zhang,
2011).
We first show simulations using our modified logistic regression model. The results from
2, 500 simulations are summarized in table 1.1. In each table, we report the averages of the
estimates (AVE), the model-based standard errors (MoSE) which are computed based on the
observed Fisher information matrices, the empirical standard errors (ESE), and the coverage
(Cov) rates of the 95% asymptotic Wald confidence intervals for the regression coefficients
and the CIFs evaluated at times 3 and 5, given that the covariates are Z1 = −1 and Z2 = 2.
The Scheike et al. (2008) model does not provide regression coefficients for covariates
like the LOG, WEI or Fine Gray models. Instead, the Scheike method provides time-varying
coefficients. As a consequence, we did not use the Scheike model when comparing regression
coefficients and their standard errors across different models.
Table 1.1 contains the results for the cause 1 and cause 2 regression coefficients β11, β12,
β21, and β22 from the two parametric models and the Fine and Gray model, as well as the
cause 1 and cause 2 CIFs F1(1), F1(3), F2(1), and F2(3) from the two parametric models,
the Fine and Gray model and the Scheike model. The true model is marked in bold letters
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in the leftmost column of the table.
When handling the LOG+PH data, as presented in panels A1 and A2 of table 1.1, our
modified logistic model has comparable or better performance than Fine and Gray’s semi-
parametric model, when it comes to estimating regression coefficients and predicting CIFs.
The Fine and Gray model shows downward bias when estimating the cause 2 regression
coefficients. To evaluate the effect of misspecifying baseline CIFs when estimating regression
coefficients and predicting CIFs, we generate the data based on a modified logistic base-
line and the proportional hazard model (LOG+PH). We then apply our proposed modified
Weibull regression model to the simulated LOG+PH data and report estimation statistics in
table 1.1. The estimation converges without significant bias, and the MoSEs are reasonable,
which is evidence that the Weibull estimation procedure has some robustness. However,
when we apply the modified Weibull baseline model to the simulated modified logistic data,
the optimization takes more time (approximately twice longer) to converge, when compared
to estimating with the modified logistic model.
We also run simulations using our modified Weibull regression model. The results from
2, 500 simulations are summarized in panels B1 and B2 of table 1.1. When the baseline CIFs
are from the modified Weibull model, the performance of our proposed modifed logistic model
is comparable to that of the modified Weibull model and of the Fine and Gray method. The
more general method by Scheike et al. (2008) also performs well, although the standard errors
provided by the package are noticeably larger than the ones from the other three models.
As shown in table 1.1, the semiparametric model of Fine and Gray (1999) underestimates
the values of β21 and β22, the regression coefficients of cause 2. As a result, the coverage of
the Wald confidence intervals is very low.
Next, we evaluate and compare the performance of the models when the proportional
hazards assumption does not hold. We adopt the generalized odds rate (GOR) transforma-
tion (Dabrowska and Doksum, 1998; Jeong and Fine, 2007) for cause 1 and cause 2 CIFs.
That is, g{F1(t; z);α1} = g{F01(t);α1}+β′1z, where g{ν;α1} = log[{(1−ν)−α1−1}/α1]. We
set α1 = 5 in our simulations. We simulate the competing cause times using α2 = 5. We con-
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Table 1.1: Simulation results where the data were simulated from our proposed modified logistic
(panel LOG + PH) or Weibull model (panel WEI + PH) with complementary log-log transformation
or with generalized odds-rate transformation (panel LOG + GOR and WEI + GOR), where AVE
is the average of the estimates, MoSE is the average of the model-based standard errors, ESE is
the empirical standard error, and Cov is the coverage rates of the 95% Wald CIs
LOG + PH βˆ11 βˆ12 Fˆ1(1) Fˆ1(3)
DIM VAR Log Wei FG Log Wei FG Log Wei FG Sch Log Wei FG Sch
300
(A1) True 0.50 0.50 0.50 0.50 0.50 0.50 0.08 0.08 0.08 0.08 0.15 0.15 0.15 0.15
AVE 0.50 0.51 0.50 0.50 0.50 0.50 0.08 0.09 0.09 0.09 0.15 0.15 0.14 0.14
MoSE 0.11 0.11 0.11 0.11 0.11 0.11 0.02 0.03 0.09 0.33 0.04 0.04 0.06 0.37
ESE 0.11 0.11 0.11 0.11 0.11 0.11 0.02 0.03 0.08 0.08 0.04 0.04 0.05 0.05
Cov 0.95 0.94 0.95 0.94 0.95 0.94 0.93 0.92 0.98 0.98 0.94 0.95 1.00 1.00
WEI + PH βˆ11 βˆ12 Fˆ1(1) Fˆ1(3)
300
(B1) True 0.50 0.50 0.50 0.50 0.50 0.50 0.19 0.19 0.19 0.19 0.35 0.35 0.35 0.35
AVE 0.51 0.51 0.50 0.49 0.51 0.50 0.18 0.19 0.19 0.19 0.35 0.36 0.36 0.36
MoSE 0.11 0.11 0.11 0.11 0.11 0.11 0.04 0.04 0.09 0.32 0.07 0.08 0.10 0.18
ESE 0.10 0.11 0.11 0.12 0.11 0.11 0.04 0.04 0.07 0.07 0.07 0.07 0.08 0.08
Cov 0.96 0.95 0.95 0.88 0.94 0.94 0.90 0.94 0.90 1.00 0.91 0.94 0.90 0.99
LOG + GOR βˆ11 βˆ12 Fˆ1(1) Fˆ1(3)
300
(C1) True 0.50 0.50 0.50 0.50 0.50 0.50 0.08 0.08 0.08 0.08 0.14 0.14 0.14 0.14
AVE 0.50 0.52 0.24 0.51 0.52 0.24 0.08 0.08 0.09 0.09 0.15 0.16 0.14 0.14
MoSE 0.24 0.26 0.11 0.25 0.26 0.11 0.03 0.03 0.06 0.36 0.13 0.14 0.07 0.36
ESE 0.21 0.21 0.11 0.21 0.21 0.11 0.03 0.03 0.06 0.08 0.04 0.05 0.07 0.06
Cov 0.93 0.94 0.32 0.94 0.94 0.31 0.91 0.92 0.92 0.99 0.96 0.97 0.92 1.00
WEI + GOR βˆ11 βˆ12 Fˆ1(1) Fˆ1(3)
300
(D1) True 0.50 0.50 0.50 0.50 0.50 0.50 0.16 0.16 0.16 0.16 0.29 0.29 0.29 0.29
AVE 0.50 0.53 0.26 0.48 0.53 0.26 0.16 0.16 0.16 0.16 0.29 0.29 0.29 0.29
MoSE 0.24 0.25 0.11 0.25 0.25 0.11 0.05 0.05 0.06 0.34 0.19 0.19 0.06 0.20
ESE 0.19 0.23 0.11 0.19 0.24 0.11 0.04 0.05 0.06 0.06 0.04 0.05 0.07 0.07
Cov 0.94 0.91 0.42 0.96 0.91 0.41 0.90 0.89 0.92 1.00 0.96 0.95 0.92 1.00
LOG + PH βˆ21 βˆ22 Fˆ2(1) Fˆ2(3)
DIM VAR Log Wei FG Log Wei FG Log Wei FG Sch Log Wei FG Sch
300
(A2) True 0.50 0.50 0.50 0.50 0.50 0.50 0.32 0.32 0.32 0.32 0.48 0.48 0.48 0.48
AVE 0.51 0.48 -0.04 0.51 0.49 -0.04 0.32 0.32 0.32 0.32 0.47 0.47 0.43 0.43
MoSE 0.09 0.09 0.08 0.09 0.09 0.08 0.07 0.06 0.20 0.20 0.07 0.07 0.07 0.13
ESE 0.10 0.09 0.08 0.10 0.09 0.08 0.07 0.06 0.08 0.08 0.07 0.07 0.07 0.07
Cov 0.94 0.96 0.00 0.95 0.95 0.00 0.94 0.94 1.00 1.00 0.94 0.94 1.00 1.00
WEI + PH βˆ21 βˆ22 Fˆ2(1) Fˆ2(3)
300
(B2) True 0.50 0.50 0.50 0.50 0.50 0.50 0.31 0.31 0.31 0.31 0.51 0.51 0.51 0.51
AVE 0.51 0.52 -0.03 0.51 0.51 -0.03 0.31 0.31 0.28 0.28 0.51 0.50 0.47 0.47
MoSE 0.10 0.09 0.08 0.10 0.10 0.08 0.06 0.06 0.09 0.21 0.07 0.09 0.10 0.11
ESE 0.10 0.10 0.08 0.11 0.10 0.08 0.06 0.06 0.07 0.07 0.07 0.08 0.07 0.07
Cov 0.95 0.95 0.00 0.95 0.95 0.00 0.96 0.94 0.90 1.00 0.95 0.94 0.90 0.99
LOG + GOR βˆ21 βˆ22 Fˆ2(1) Fˆ2(3)
300
(C2) True 0.50 0.50 0.50 0.50 0.50 0.50 0.26 0.26 0.26 0.26 0.46 0.46 0.46 0.46
AVE 0.51 0.58 -0.10 0.51 0.58 -0.09 0.27 0.27 0.26 0.26 0.46 0.47 0.47 0.47
MoSE 0.28 0.32 0.07 0.29 0.32 0.07 0.06 0.06 0.07 0.23 0.13 0.14 0.07 0.11
ESE 0.24 0.27 0.07 0.23 0.27 0.07 0.06 0.06 0.07 0.07 0.05 0.05 0.07 0.07
Cov 0.95 0.96 0.00 0.96 0.96 0.00 0.94 0.94 0.92 1.00 0.96 0.97 0.95 0.98
WEI + GOR βˆ21 βˆ22 Fˆ2(1) Fˆ2(3)
300
(D2) True 0.50 0.50 0.50 0.50 0.50 0.50 0.29 0.29 0.29 0.29 0.51 0.51 0.51 0.51
AVE 0.45 0.52 -0.07 0.51 0.52 -0.07 0.29 0.29 0.29 0.29 0.52 0.51 0.51 0.51
MoSE 0.28 0.29 0.07 0.29 0.29 0.07 0.06 0.06 0.07 0.21 0.18 0.19 0.07 0.10
ESE 0.27 0.26 0.07 0.19 0.26 0.07 0.06 0.06 0.07 0.07 0.05 0.05 0.07 0.07
Cov 0.94 0.92 0.00 0.98 0.92 0.00 0.92 0.90 0.92 1.00 0.97 0.95 0.95 0.97
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sider both the modified logistic and modified Weibull functions for the baseline CIFs when
generating the data. We then fit our modified logistic and modified Weibull models with the
generalized odds-rate transformation, the Fine and Gray method and the semiparametric
model by Scheike et al. (2008) to the simulated LOG+GOR and WEI+GOR data.
When estimating the LOG+GOR data, our modified logistic model does well, although
the Fine Gray model has lower MoSEs when estimating F1(3) and F2(3), as seen in panels
C1 and C2 of table 1.1. We estimate a relatively high number of parameters (the center of
rising and steepness of the two baseline models, the four regression coefficients, α1 and α2).
This allows us to test our parametric model in conditions similar to those of the analysis of
a new dataset. The somewhat higher MoSEs of some of the predictions obtained from the
parametric models may be a reflection the number of parameters in the model. As before,
the Scheike model tends to overestimate the standard errors in their CIF estimators. The
modified Weibull model can handle data generated from the modified logistic baseline model,
although the MoSEs when estimating the regression coefficients are a bit higher than when
using the modified logistic model.
As the proportional hazards assumption is clearly violated, the Fine and Gray method
results in downward bias when estimating covariate effects. Because the Fine and Gray
model is a semiparametric approach, the misspecified covariate effects may be compensated
by the nonparametric estimation of the baseline CIF. As a consequence, the predicted CIF
is close to the true value despite the misspecified covariate effects.
We now turn to the WEI+GOR simulations presented in panels D1 and D2 of table
1.1. Again, our modified Weibull model does quite well, although the MoSEs for F1(3) and
F2(3) are larger than those of the Fine and Gray model. The modified logistic model again
does well when used to estimate data generated from the Weibull baseline model. The Fine
and Gray method again seriously underestimates regression coefficients, although its CIFs
predictions are satisfactory. When the true data are from the modified Weibull model, the
modified logistic model performs well. Our modified Weibull model performs just as well
as the modified logistic model does. Both work well for the sample of size 300 and clearly
outperform the general semiparametric model by Scheike et al. (2008). The Scheike model
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overestimates the variability in predicting CIFs, so that its coverage rate is close to 1. The
coverage rates of regression parameters from the Fine and Gray method are much lower than
the nominal level.
1.4 BREAST CANCER STUDY DATA ANALYSIS
Having developed our modeling framework, we now turn to applying our proposed models to
the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Study (NSABP B-
14). This study investigated the effects of tamoxifen for node negative and hormonal receptor
positive patients. The data contain information on time (in years), event (0=censored,
1=recurrence, 2=other events), treatment group (trt=1, placebo; trt=2, tamoxifen), age,
and tumor size (through variable tsize), for 2,582 eligible patients who had follow-up and
known tumor sizes. Recurrence is the event of interest and other events are treated as
competing ones.
Of the 2,582 patients enrolled in the study, 1,276 (49.4 %) were censored, 577 (22.3 %)
had a recurrence of their cancer, and 729 (28.2 %) had other events. 1299 (50.3 %) of the
study participants were in the placebo group, whereas 1283 (49.7 %) of the participants were
in the tamoxifen group. The age of the participants ranges between 25 and 75 years of age
with a median of 56 years of age and an interquartile range (IQR) of 16 years. Tumor size
ranges between 3 and 135, with a median of 20 and an IQR of 13. Tumor size shows 18 mild
outliers. These observations are identified as mild outliers because they are greater than
75th% tile +1.5× IQR. Tumor size also shows 9 severe outliers, defined as such because they
are greater than 75th% tile +3 × IQR. Hence, tumor size is top-coded before running the
analyses. That is, the top 10% of tumor size values are set respectively to the value of the
1st 90th percentile. Topcoding is often called censoring. Censoring and robustness methods
are presented in Tukey (1979b) and Tukey (1979a).
We investigate the statistical associations among covariates. The placebo and tamoxifen
groups are well-balanced when considering the age of the participants. A t-test fails to reject
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the hypothesis of equal average age across the treatment groups (t=.34, p=.73). The median
age is 57 years (IQR=16 years) in the placebo group, and 54.8 years (IQR=15 years) in the
treatment group. A t-test fails to reject the hypothesis of equal average tumor size across the
treatment groups (t=-.43, p=.67). Median tumor size is 20 (IQR=14) in the placebo group,
and 20 (IQR=12). Tumor size has more severe outliers (8) in the tamoxifen group than in
the placebo group (1). The mild outliers of tumor size are more or less evenly distributed
among the two randomization groups. The correlation between age and tumor size is small
(-.05), but statistically significant (p=.01).
Before fitting the data, we code trt=0 for placebo and trt=1 for tamoxifen, and center
the age at mean 55 and tumor size at mean 22. The likelihood is maximized on all the
parameters of the two distribution, as well as on α1 and α2. We fit cause 1 and cause 2
regressions simultaneously, but for clarity’s sake, we present the results separately in the
following sections. We emphasize the presentation of the competing cause because Shi et al.
(2013) investigated cause 1 in details.
1.4.1 Cause 1 regression coefficients
The cause 1 coefficients in our work are modeled in a fashion similar to that of Shi et al.
(2013). As expected, the cause 1 coefficients we estimated were very close to those of Shi
et al. (2013).
We first run the Kolmogorov-Smirnov test and the Cramer von Mises test for time in-
variant effects of treatment group, age and tumor size (Scheike et al., 2008). The assumption
of proportional hazards for subdistribution does not hold for age. Hence we apply our mod-
ified logistic model and the modified Weibull model with the GOR transformation to the
breast cancer data. The Fine and Gray (1999) model is also included for comparison because
our simulations suggest that this model can have good prediction on CIFs even though the
estimates of the regression coefficients may be biased.
As shown in table 1.2, the cause 1 coefficient estimates and standard errors obtained
from the modified logistic model and the modified Weibull model are generally close to each
other, and the coefficient estimates from the Fine and Gray model are a bit larger than those
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from the parametric models. However, the p values from the three models are comparable
and fairly small for all three prognostic factors. The coefficients for treatment and age are
all negative while those for tumor size are all positive across the three models. This suggests
that the patients who were older, received Tamoxifen treatment and had smaller tumor sizes
were less likely to have cancer recurrence.
Next, we select two patient cases to compare the predicted CIFs from the four models.
Patient I has good prognostic factors: Tamoxifen (trt = 1), 65 years old (age = 10) and
tumor size 12 (tsize = -10), while patient II has poor prognostic factors: placebo (trt = 0),
45 years old (age = -10) and tumor size 32 (tsize = 10). The four predicted CIFs are plotted
in Figure 1.1. The solid lines are the estimated CIFs from 0 to 20 years from the modified
logistic model, the dashed lines are for the modified Weibull model and the dotted lines are
from Fine and Gray’s model. The estimated CIFs of the Scheike semiparametric model are
represented by the gray lines. We first observe that the CIF curves only have one bend point.
The predicted 20 years recurrence rate is somewhere between 0.1 and 0.2 for patient I and
somewhere between 0.3 and 0.4 for patient II based on the parametric and the Fine Gray
models. In the figure, we also include the confidence bands (gray dashed lines) from the
Scheike et al. model, which are available from the R package timereg. The estimated CIFs
of the parametric models and of the Fine Gray models lie between the confidence bands of
the Scheike et al. model, though the confidence bands are likely to be conservative.
An exploratory Cox regression is run to evaluate the covariate effects on the hazard of
local recurrence. The coefficients in the Cox regression were consistent with those of the
CIF-based analyses.
1.4.2 Cause 2 regression coefficients
We first run the Kolmogorov-Smirnov test and the Cramer von Mises test for time invariant
effects of treatment group, age and tumor size (Scheike et al., 2008).
The assumption of proportional hazards for subdistribution holds for age. On the left-
hand panel of figure 1.2, we show the time-varying coefficient estimate for age (solid line)
along with its 95 % pointwise confidence intervals (broken lines) and 95% confidence bands
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Table 1.2: The estimates of the Causes 1 and 2 regression coefficients for the Breast Cancer Study
based on our proposed modified logistic (Log) and the modified Weibull (Wei) with generalized
odds-rate transformation, and the Fine-Gray model (FG).
βˆ1 trt βˆ1 age βˆ1 tsize
VAR Log Wei FG Log Wei FG Log Wei FG
Est -0.82 -0.69 -0.48 -0.02 -0.02 -0.01 0.04 0.05 0.02
Stderr 0.16 0.15 0.09 0.01 0.007 0.004 0.01 0.010 0.003
Z -5.15 -4.68 -5.60 -3.22 -3.38 -2.58 6.05 4.94 7.40
p value <0.001 <0.001 <0.001 <0.001 <0.001 0.01 <0.001 <0.001 <0.001
βˆ2 trt βˆ2 age βˆ2 tsize
VAR Log Wei FG Log Wei FG Log Wei FG
Est -0.23 -0.63 0.02 0.038 0.021 0.03 0.013 0.013 -0.005
Stderr 0.15 0.17 0.07 0.007 0.006 0.004 0.007 0.006 0.003
Z -1.50 -3.66 0.23 5.86 3.31 7.50 1.95 1.74 -1.67
p value 0.13 <0.001 0.81 <0.001 <0.001 <0.001 0.06 0.08 0.10
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Figure 1.1: Estimates of CIFs for two example patients using the breast cancer study dataset
(dotted lines). The age effect is not time-varying. The timereg package also outputs the
test process for the null hypothesis α(t) being a constant. The solid line on the right panel
of the figure represents the test process based on the estimated time-varying coefficient
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T (t, αˆ) = αˆ(t) − 1
τ
∫ τ
0
αˆ(t)dt, where t is some reasonably large time point. The gray area
corresponds to the simulated test processes under the null hypothesis. There is no clear
departure from the null in the observed test process.
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Figure 1.2: Estimates of time-varying coefficient for age in the cause 2 regression using the Breast
cancer study dataset
It is not clear if the assumption of proportional hazards for subdistribution holds for
treatment. Figure 1.3 shows the estimated time-varying coefficient for treatment. The
treatment effect may be time-varying, as there is some departure from the null in the observed
test process.
Figure 1.4 shows the estimated time-varying coefficient for tumor size α(t) in the Breast
cancer Study using Scheike et al.’s model. As shown on the right panel, the observed test
process (solid line) shows departure from the test processes simulated under the null hy-
pothesis. Thus the assumption of proportional hazards for subdistribution does not hold for
tumor size.
To handle the departure of the proportional subdistribution hazards assumption for
tumor size, we run a stratified Fine and Gray model (SFG) proposed by Zhou and Fine
(2011), and the standard Fine and Gray model including treatment, tumor size, age as well
as the time by tumor size interaction (FGt). The estimated coefficients are summarized in
table 1.3. The coefficient estimates for treatment and age are almost identical under these
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Figure 1.3: Estimates of time-varying coefficient for treatment in the cause 2 regression using the
Breast cancer study dataset
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Figure 1.4: Estimates of time-varying coefficient for tumor size in the cause 2 regression using the
Breast cancer study dataset
three models.
We apply our modified logistic model and the modified Weibull model with the general-
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Table 1.3: The estimates of the Cause 2 regression coefficients for the Breast Cancer Study based
on the Fine-Gray model (FG), the Fine-Gray model with tumor size by time interaction (FGt),
and the stratified Fine-Gray model (SFG)
βˆ2 trt βˆ2 age βˆ2 tsize βˆ2 tsize∗t
VAR FG FGt SFG FG FGt SFG FG FGt SFG FGt
Est 0.02 0.02 0.02 0.03 0.03 0.03 -0.005 0.01 - -0.002
STD 0.07 0.07 0.07 0.004 0.004 0.003 0.003 0.006 - 0.0006
z value 0.23 0.21 0.29 7.50 7.49 8.01 -1.67 1.93 - -3.19
p value 0.82 0.83 0.80 <0.001 <0.001 <0.001 0.12 0.05 - .001
ized odds-rate transformation to the breast cancer data. The Fine and Gray (1999) model is
also included for comparison. The estimated coefficients using our proposed modified logistic
(Log) and the modified Weibull (Wei) with generalized odds-rate transformation, and the
Fine-Gray (FG) model for cause 2 are summarized in table 1.2.
As shown in table 1.2, the cause 2 coefficient estimates and standard errors obtained from
the modified logistic model and the modified Weibull model are generally close to each other.
However, the parametric models find the treatment group to have a statistically significant
effect, whereas the Fine Gray model does not find the treatment group to have a statistically
significant effect. To better understand this discrepancy, we ran a model with trt and
trt× time as predictors. The estimate of the trt effect was −0.28 and statistically significant
(p = 0.05), which is close to the estimates of the parametric models. The trt× time effect was
also statistically significant (p=0.02). All three models agree to find age to be statistically
significant, and provide similar estimates for the effect size. None of the models seems to
find tumor size to be significant.
The coefficients for treatment are negative in the parametric models, while those for age
are positive across the two parametric models. This suggests that the patients who received
Tamoxifen treatment, and were younger were less likely to have an event such as death or
second primary cancers, according to the parametric models.
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A Cox regression was run in order to better determine the effect of covariates, and par-
ticularly of the Tamoxifen treatment on the cause 2 events. The regression coefficient for
age is similar when using Cox Regression, our parametric models, and the Fine Gray model.
The regression coefficient for tumor size is not statistically significant when using Cox re-
gression, which is consistent with our parametric models, and the Fine and Gray model.
The Cox regression treatment effect is negative (-0.13) and borderline statistically signifi-
cant (p = 0.08). Our parametric models find the treatment effect to be negative (-0.3 and
-0.6) and statistically significant (p = 0.03 and p<0.01). But the Fine Gray model does not
find the treatment effect to be statistically significant (p = 0.8). When using Fine Gray with
a treatment by time effect, the estimate of the treatment effect was -0.28 and statistically
significant, and the treatment by time effect was positive and also statistically significant.
Therefore, there is some evidence showing that Tamoxifen lowers the risk of other events.
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Figure 1.5: Nonparametric estimates of cause 2 CIF curves for Placebo and Tamoxifen groups
On Figure 1.5, we plot nonparametric estimates of the cause 2 CIF curves for the placebo
and the Tamoxifen groups. The curve of the Tamoxifen group is below that of the placebo
group, showing a small effect of Tamoxifen on the incidence of other events.
23
1.4.3 Model Discussion
In this first part of this dissertation, we focused on the joint regression modeling of two
cumulative incidence functions under an additivity constraint. We have proposed a para-
metric regression model using a flexible baseline function and a proportional hazard or a
generalized odds rate model for covariate effects. The primary advantage of our parametric
model is that it explicitly incorporates the additivity constraint between the asymptotes of
the CIFs from the primary and secondary causes for any given covariates. Our parametric
model provides a robust alternative to its semiparametric counterparts: it not only accounts
for nonproportionality but also provides a reliable variance estimator. Furthermore, it does
not require the modeling of censoring times.
We assessed the robustness of our proposed models by considering such baseline functions
as the modified logistic and the modified Weibull. Likelihood for the modified logistic model
is 6085.6, whereas likelihood for the modified Weibull model is 6091.7. The likelihoods of
the two models are very close, so that no one of our two models seems better than the other
in this data example.
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2.0 STATISTICAL ANALYSES OF PILL-MONITORING DATA
2.1 INTRODUCTION
The objective of this chapter is to present several analyses of data collected via an electronic
medication-event monitoring device. The device in question is a medication bottle which
records the times when it is opened.
In medication bottle opening events studies, data include event times, which are corre-
lated within individuals. The focus can be on the durations between events, the durations
between the baseline and the events, or the number or rates of events. In simple cases, the
data-generating process can be modeled by a renewal process. In more complex situations,
the events can display short term dependence, or present a between-individual dependence
structure. The wide range of data situations gives way to numerous approaches when it
comes to model specification and estimation.
There are many reasons why some patients do not follow their drug regimen. They may
forget to take their drugs. They may have difficulties managing several medications with
different dosing regimens. A patient with an asymptomatic disease, such as high blood pres-
sure or high cholesterol, may believe that the treatment is no longer needed. Patients may
skip doses or stop taking medications because of their side effects. Elderly patients may
have memory-loss or even dementia. Medical non-adherence has direct health consequences
as well as costs related to the complications of the chronic condition. For high blood pres-
sure, it could be a cerebrovascular accident; and for Type 2 diabetes, it could be heart disease.
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Medication adherence is generally computed over some interval of time as the percentage
of correct medication administrations over the total number of prescribed administrations.
When observed in a group of subjects, the distribution of medication adherence is often J-
shaped. That is because most study participants correctly follow their medication regimen,
but some take no medication, and others miss some doses. J-shape distributions are quite
different from Gaussian distributions, so that parametric techniques utilizing a normal distri-
bution can be inadequate, especially in small sample size situations. For example, measures
of central tendency fail to provide an adequate summary of the distribution.
Summarizing and analyzing the hundreds of data points per subject which are often col-
lected in medication bottle opening events studies is challenging. Several statistics can be
used including the average or the median adherence over a given interval, often three weeks.
Some study reports provide an indicator of the spread of the distribution of adherence. This
is adequate if adherence is relatively constant within the interval, or if the changes in ad-
herence across time are not of great interest. However, patients can behave differently as
time progresses. The behavior of patients often changes as they are affected by stress and
fatigue during the week, then have time to take better care of themselves over the weekend.
If adherence rates increase or decrease within the intervals, then simple descriptive statistics
will not properly summarize the data.
One approach to analyze adherence data is to categorize the percentage of correct dose
administrations into two groups. However, some potentially significant changes occuring
across time can then go unnoticed, because the threshold is not crossed. 80% is often con-
sidered the lowest percentage of correct doses for a good adherer. A patient who progresses
from 20% to 70% adherence will be considered a poor adherer throughout the study, despite
a substantial improvement after the intervention.
A different method was developed by Rohay (2010) who used a mixture of beta distri-
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butions to describe the distribution of the adherence of several patients. The author used
the expectation-maximization algorithm to obtain parameter and standard error estimates
of that distribution. The parameters can be used to characterize the pill taking behavior
of different groups of participants, so that this approach can be of great interest to study
investigators. On the other hand, this analysis can be computationally intensive.
As indicated by Knafl GJ (2004), another assessment of medication adherence across
time can be obtained by grouping observation days and computing counts and rates over
separate periods of cap use. To do this, the analyst divides the observation period into
intervals, counts the number of openings (or the number of adherent days in each interval),
and obtains the opening rate for the interval. The patterns of adherence can then be studied
across time using splines fitted onto the observations of number or rates of openings. The
polynomial curves are of interest for several reasons. First, power terms in the polynomial
can be added or removed from the model using the maximization of a score function. Second,
an alternative measure of the participant's adherence may be obtained by calculating the
smoothness of the polynomial fit to the participant's count data.
This part of the thesis looks at adherence data via the analysis of time between two
medication bottle openings (also called gap times). To this end, we largely focus on frailty
models. Frailty models can be used for duration data, and are characterized by the inclusion
of a random effect, that is, an unobservable random variable which represents the hetero-
geneity of observations coming from the same cluster. A cluster can be a family of several
individuals who share genetic factors, for example. In our recurrent events study, the cluster
is the individual with his or her psychosocial and behavioral characteristics.
Proportional hazards models (Cox, 1972a) were extended to frailty models (Andersen
et al., 1995; Hougaard, 1995; Sinha and Dey, 1997), which are characterized by the presence
of a random effect. Vaupel et al. (1979) presented the frailty term in the context of univari-
ate survival models, while Clayton (1978) and Oakes (1982) generalized frailty modeling to
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multivariate survival models.
The rest of the thesis is organized as follows. We review several models for the analysis
of gap times in section 2.2. We describe the analysis of a prescription bottle event dataset
in section 2.3. An exploratory cluster analysis of survival curves is presented in section 2.4.
We indicate the directions of our future work in section 2.5.
2.2 MODELS
2.2.1 Modeling of gap times
We assume that individual i is observed over the time interval [0, τi] and that w = 0 corre-
sponds to the start of the event process. The gaps Tij between events have hazard function
λ(t|xi), where xi is a covariate. If ni events are observed at times 0 < wi1 < · · · < wini ≤ τi,
let tij = wij − wi,j−1, with j = 1, . . . , ni. These are the observed gap times for individual i
with the final time being possibly censored. Let ti,ni+1 = τi − ti,ni .
The likelihood function from m independent individuals is of the form
m∏
i=1
{
ni∏
j=1
λ(tij|xi) exp (−Λ(ti,j|xi))
}
exp (−Λ(ti,ni+1|xi)) ,
where λ(tij|xi) is the hazard and Λ(ti,j|xi) is the cumulative hazard.
We now review several model formulation for the analysis of the times between medication
administrations.
28
2.2.1.1 Cox regression The Cox semiparametric multiplicative hazards model in which
the hazard function given Xi is of the form
λ(t|Xi) = λ0(t) exp(βTXi),
where λ0(t) is the baseline hazard function.
The basic assumption in Cox's proportion hazard model is that the survival time of
subjects are independent. This assumption is violated in pill monitoring studies as the
collected gap times exhibit correlation. A naive use of the Cox model in a pill monitoring
study would greatly inflate the sample size and the power of the analyses. The sample size
could erroneously be taken to be equal to the number of bottle openings. In order to use
the simple Cox model, the analyst would have to only use one observation, or one summary
measure of the observations, per study participant.
2.2.1.2 Accelerated failure time models Let T be a response time, and define Y =
log(T ). An accelerated failure time (AFT) model is of the form:
Y = β0 + x
′β + σ, (2.2.1)
where x = (x1, . . . , xk)
′ is a covariate vector, β = (β1, . . . , βk)′ is a vector of regression
coefficients, σ>0 is a scale parameter, and  is a random variable whose distribution is
independent of x. When  has standard extreme value, logistic, and normal distributions, T
has Weibull, log-logistic, and log-normal distributions, respectively. Because of the absence
of frailty, only one observation per ID or an ID level summary measure can be used. One
approach is to average the gap times of an individual and use that mean value as a summary
measure.
2.2.1.3 Frailty models with nonparametric baseline function The heterogeneity
of the times to openings can lead to trouble insofar as parameter estimates can be inconsis-
tent, standard errors can be wrong, and estimates of duration dependency can be misleading.
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Frailty terms seek to explicitly account for the extra variance associated with the variability
of the gap times within each prescription bottle user.
Consider a survival regression model with hazard λ(t|θ, β), where θ is a vector-valued
parameter and β is a regression parameter. Assume that the random variable U , with density
g(ui|σ2) denotes the unobservable individual frailties and that E(U) = 1 and V (U) = σ2 .
The random effect needs to be integrated out. The likelihood is:
L(θ, β, σ2) = Πni=1
∫ ∞
0
λ(ti|ui, θ, β)δiS(ti|ui, θ, β)g(ui|σ2)dui,
where δi is the censoring indicator.
We can modify Cox's model into the form λij(t) = λ0(t)ui exp(xijβ) where the uis are
log-normal with a mean parameter equal to 0. Observations j within cluster i share the
frailty ui, and fail faster (hence the term frailty) than average if ui > 1.
Another way to write this frailty model is as
λij(t|bi) = λo(t) exp(xijβ + bi), where bi ∼ N (0, σ2), (2.2.2)
and where observations j are in clusters i, and bi is uncorrelated with bi′ . The spread of bi
quantifies the variability of the occurrence rate between individuals.
Therneau and Grambsch (2000) introduce an interesting model which assumes a frailty
whose distribution is gamma with parameters ( 1
α
, 1
α
). α quantifies the amount of heterogene-
ity among subjects. If α is large, variability among individuals is high, and the values of the
variable will be close to 1. On the other hand, a small α implies low heterogeneity among
the observations individuals within the cluster.
The clustering is modeled by the random effect ξi. The gap time has intensity function
λij(t|ξi) = ξiλo(t) exp(xijβ), (2.2.3)
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where ξi ∼ Γ
(
1
α
, 1
α
)
i.i.d., E(ξi) = 1, and Var(ξi) = α. The difference between (2.2.2)
and (2.2.3) is the distribution of the random effect. The frailty term can be specified in an
additive way, as in (2.2.2), or in a multiplicative fashion, as in (2.2.3).
Instead of choosing ξi in (2.2.3) to be distributed as i.i.d. gamma random variables,
one can use for example a positive stable, an inverse gaussian, or a power variance function
distribution (Duchateau and Janssen, 2008; Wienke, 2010). While being able to choose be-
tween different frailty distributions is useful, we are going to focus on the model form with
the normal frailty, such as in (2.2.2). That model provides a simpler framework for modeling
multiple and correlated random effects.
We note that the individual frailty is modeled as an extra risk that the medication
bottle is opened. As such, the frailty is related to relative adherence. The individual frailty
measures the adherence of the individual when compared to the sample.
2.2.1.4 Modeling of the random effects As presented in Therneau and Grambsch
(2000), a more general frailty model is:
λ(t) = λ0(t)e
Xβ+Zb, where b ∼ G(0,Σ(θ)),
where λ0 is the baseline hazard function, X and Z are the design matrices for the fixed and
random effects, respectively, β is the vector of fixed-effects coefficients and b is the vector
of random effects coefficients. The random effects distribution G is modeled as Gaussian
with mean zero and a variance matrix Σ, which in turn depends on a vector of parameters
θ. We start with the simple model characterized by one random intercept per individual.
Z is the one-way ANOVA design matrix. Zij = 1 if gap time j is that of individual i. A
more complex model would require the individuals to be nested within a group, such as an
enrolling center, or a hospital.
We may want to test the significance of the random effects. In order to test, we fit the
model without one of the random effects and compare the integrated likelihood, which we
denote L, for the two fits. The following chi-square statistic is computed:
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2 log(Lmodels)− 2 log(Lmodell) ∼H0 χ2(dfmodels−dfmodell) ∼ χ2(dfs−dfl) ∼ χ2diff .
Here, s denotes the smaller model with fewer parameters, whereas l denotes the larger
model with more parameters. This χ2diff diff-value is distributed with dfdiff degrees of freedom
and can be checked for significance.
2.2.1.5 Cox frailty model with time-varying covariate Investigators are often in-
terested in studying the dynamics of time to administration as study time increases. Several
authors have pointed out that a patient's adherence decreases as the novelty feel of the
treatment and prescription bottle wears out and between clinic visits Cramer et al. (1990);
Feinstein (1990); de Klerk et al. (2003). Such a behavior is often called the “white coat”
effect.
Let TiSt denote the time a patient has been in the study, or the time a patient has been
using the prescription bottle, whichever is available from the data set. The hazard function
can be written as:
λij(t) = λ0(t) exp(xiβ + TiStijβt + bi), where bi ∼ Normal(0, σ2) . (2.2.4)
Alternately, the frailty effect can be specified as a gamma distribution:
λij(t|ξi) = ξiλo(t) exp(xiβ + TiStijβt), (2.2.5)
where ξi ∼ Γ
(
1
α
, 1
α
)
i.i.d., E(ξi) = 1, and Var(ξi) = α
2.2.1.6 Frailty models with parametric baseline function We now turn to frailty
models with parametric baseline hazard functions. The frailty model is defined in terms of
the conditional hazard
λij(t|ui) = h0(t)ui exp(xijβ), (2.2.6)
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where h0 is the baseline hazard function. Following Munda and Legrand (2012), we consider
a Weibull distribution for the baseline hazard. The Weibull hazard function is specified as
h(t; ρ, ν) = ρνtρ−1, with ρ>0 and ν>0.
Again following Munda and Legrand (2012), we set the frailty term to be a gamma
random variable U with probability density function:
f(u; θ) =
u1/θ−1 exp(−u/θ)
Γ(1/θ)θ1/θ
, θ>0.
The variance of the frailty term U is θ.
2.2.2 Counting processes
The focus in this section is to analyze counts of bottle events within a particular window
of time, rather than gap times. Let i = 1 . . . n note independent subjects. Ni(t) counts the
number of events for the period of time [0, τi], for subject i.
An interesting quantity is the mean cumulative function (MCF) of the number of medi-
cations taken by the patients. The MCF is a staircase function that depicts the cumulative
number of medication administrations over time. The cumulative mean function provides
a graphical representation of the degree of medication adherence for each patient. It can
be used to compare the compliance of two of more patients. Furthermore, the cumulative
mean function can be estimated for groups of patients, thus enabling group comparisons. To
our knowledge, the MCF has not been used to represent or analyze medication adherence
datasets.
2.2.2.1 Bayesian estimation of Cox regression with random effects Following
Nielsen et al. (1992), we formulate the frailty model using the counting process notation.
For subjects i = 1, . . . , n, we observe processes Ni(t) which count the number of events which
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have occurred up to time t. The corresponding intensity process Ii(t) is given by
Ii(t)dt = E(dNi(t)|Ft−),
where Ft is a filtration.
We model the clustering of gap times within patients by introducing a frailty term into
the proportional hazards model. In counting process notation, this gives
Ii(t)dt = Yi(t) exp(βxi + bi)dΛ0(t), where, bi ∼ Normal(0, 1/θ) .
We observe dataD = (Ni(t), Yi(t), xi), i = 1, . . . , n and parameters β, Λ0(t) =
∫ t
0
λ0(u)du
is to be estimated non-parametrically. The joint posterior distribution of the model is defined
by
P (β,Λ0()|D) ∼ P (D|β,Λ0())× P (β)× P (Λ0()).
A non-informative gamma prior can be assumed for θ, the precision of the frailty parame-
ters. To our knowledge, the Bayesian frailty model has not been used to analyze prescription
bottle events datasets.
2.2.3 Software
The Cox model is handled by the functions of package coxph in R. The survreg function in
package survival can fit an accelerated failure time model.
Frailty models can be handled by packages coxph, frailtypack, parfm, and coxme in
R. Coxph can fit frailty models with a random effect drawn from a gamma distribution.
In frailtypack, a random effect, and a random slope can be fitted. The random effects
can be gamma or log-normal. The baseline function λ0(T ) can be semiparametric, piecewise
constant, or parametric Weibull. In addition, frailtypack allows the analyst to compare
the AIC from different model specifications to determine the best fit for the data. Pack-
age parfm fits frailty models with parametric baseline hazard functions. Possible baseline
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hazards are Weibull, inverse Weibull, exponential, Gompertz, log-normal and log-logistic.
Possible frailty distributions are gamma, inverse Gaussian, positive stable and log-normal.
Coxme allows the analyst to compare the AIC from different model specifications to deter-
mine the best fit for the data.
SAS's proc reliability provides the mean cumulative function, as well as confidence in-
tervals. Regression analyses for recurring events data sets can also be run via SAS's proc
reliability. Bayesian Cox regression models can be handled by BUGS.
2.3 ANALYSIS OF DATA
This section applies frailty models to the data set of the Evaluation of Adherence Interven-
tions in Clinical Trials (NIH-HL48992) study, a randomized controlled trial which we refer
to as the ACT study. The ACT Study recruited 180 adults. The participants were given
their medication in Medication Event Monitoring System (MEMS)-capped bottles contain-
ing a computer chip, which records each time the prescription bottle is opened. All subjects
had a prescribed regimen of 1 dose/day. The cap opening times recorded were presumed to
coincide with medication-taking.
The ACT study was nested within the Effect of Cholesterol Lowering on Behavior (or
CARE) study (NIH-HL46328), a gender-balanced, randomized, controlled trial, where the
180 subjects were randomized either to a lipid lowering drug (90 subjects), or to a placebo (90
subjects). The participants of the CARE study continued into the ACT study, where they
were randomized to one of three groups: controls, habit training, or habit training/problem
solving. The behavioral training delivered to the habit training, and to the habit train-
ing/problem solving subjects aimed to improve their medication adherence. All subjects
were prescribed a once-a-day medication regimen. There were 59 subjects in the controls
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group, 63 in the habit training group, and 58 in the habit training/problem solving group.
Data were collected over a six month period. Available variables include electronically
monitored events (MEMs), published self-report inventories (Morisky, Shea, Haynes), spe-
cific recall over one day, one week, one month, and six months, as well as pill counts.
Overall, the sample was evenly distributed by gender (53.4% male), predominantly white
(87.8%), and middle-aged (mean age=46.2 years). Most subjects (68.2%) were married, and
75.4% of the subjects were employed full or part time. The subjects were well-educated,
with 98.9% of them having a high school diploma/GED or more education.
The missingness rate is very low in the sociodemographic, and electronic event monitor-
ing variables. No data inconsistencies are detected. The length of use of the MEMS caps
ranges between 0 and 9.5 months, with an average of 6.0 months, and a standard deviation
of 1.4 months. Summary adherence is computed as the ratio of the number of openings over
the number of days observed. When the number of medication administrations is greater
than the number of days, the computed adherence is higher than 1. Summary adherence
ranges between 0.02 doses per day and 1.44 doses per day, with a median of 0.99 doses per
day and an interquartile range of 0.31 doses per day.
2.3.1 Exploratory data analysis
The histogram of the gap times across all the observations of all the subjects is in Figure 2.1.
The time unit of interest is hours. The distribution of the gap times shows a protuberance
between 0 and 3 hours, a very high spike around 24 hours, and two bumps of decreasing
sizes around 48 and 72 hours. The distribution of the gap times does not seem to lend itself
to simple parametric modeling. The histogram of the log gap times, shown in Figure 2.2,
appears to be that of a mixture of several time distributions. From that standpoint, the
nonparametric baseline hazard approach is appealing.
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Figure 2.1: Histogram of gap times
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Figure 2.2: Histogram of log gap times.
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We plot individual survival curves of gap times in figures 2.3 and 2.4. These curves
show various pill-taking behaviors. ID 1328's gap time survival curve drops from around
.98 to around 0.05 very steeply around 24 hours. ID 1328 is thus very good at taking their
medication with a gap time consistently around 23 to 24 hours.
ID 1517's gap time survival curve shows several drops between time 0 and 72 hours. A
relatively small drop before time 2 hours shows that the medication bottle was opened several
times in the space of a couple of hours. This is not consistent with a once-a-day medication
regimen. Perhaps the participant forgot they had already taken their medication, or was
experimenting with the prescription bottle, or the participant was pocketing the dose for the
next day. A fairly large drop of the survival curve is seen around 24 hours, consistent with
the subject opening the bottle once-a-day for some of the days of the experiment. Another
small drop of the survival curve around 48 hours shows that the subject forgot their medi-
cation some of the days, or was taking the medication they had pocketed. Another smaller
drop around 72 hours shows that the bottle was not opened for a duration of 3 days for some
part of the experiment.
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Figure 2.3: ID 1328's individual survival curve.
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Figure 2.4: ID 1517's individual survival curve.
Figure 2.5 shows the survival curve of the entire sample. The survival curve shows a slow
decrease during the first 24 hours, indicating that some patients will open their prescription
bottle in the first 24 hours after their previous medication administration. The survival curve
then shows a large and steep drop around 24 hours. This indicates that patients tend to
have the habit of taking their medication around the same time of the day. Perhaps around
breakfast time, lunch, or possibly bedtime.
The survival curve shows a smaller, but steep drop around 48 hours. This indicates that
some patients will forget their dose the first day, but then successfully take their medication
at their usual time of the day on the second day. A much smaller drop is seen around 72
hours. This indicates that some patients will forget their dose on both the first and second
day, but then successfully take their medication at their usual time of the day on the third
day. Those patterns can also be seen on the hazard plots.
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Figure 2.5: Survival curve for the entire sample
2.3.2 Proportional hazard assumption
We plot the Kaplan-Meier survival curves for each gender in order to check the proportional
hazard assumption. The plots are shown in figure 2.6. The female survival curve is for
the most part above the male survival curve by a small distance which is about the same
throughout time. Therefore the proportional hazard assumption seems to hold for gender.
2.3.3 Model comparison and covariate selection
Tables 2.1 and 2.2 show the results of analyses run using parametric and nonparametric
models. Gender is found to be statistically significant or to approach significance in all
models. The intensity function of the frailty models is higher for male participants, rela-
tive to female participants, indicating that the time between medication administrations is
longer for females. The accelerated failure time model is run using individual-level average
gap times, so that the effect of the time spent in study cannot be assessed. Time in study
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Figure 2.6: Survival curves by gender.
was calculated in months. The three frailty models (2.2.6), (2.2.4), and (2.2.5) find time in
study to be statistically significant. The regression coefficient for Time in study is negative,
indicating that as Time in Study passes, intensity goes down, and thus the time between
medication administrations increase.
2.3.4 Interpretation of the random effect
In this section, we focus on models which use Gaussian distributed frailties. The “frailty” of
subject k can be interpreted as an excess noncompliance fk = exp(bk) in taking medication
for individual k. The random individual effect in our model has a standard deviation of .30.
We can expect about 15% of the subjects to be 1 standard deviation below the mean, and
these individuals will have a noncompliance that is exp(1 × .30) = exp(.30) = 1.35 greater
than the norm. This is a modestly large individual effect.
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We obtain estimates of the frailties for all the subjects. The lowest frailty is -1.0, the
highest is 0.46, and the mean is 0. In the context of this adherence study, low frailties
indicate subjects with longer gap times and thus poorer adherence behavior. ID1139 whose
survival curve is shown in figure 2.7 is a poor adherer whose gap time distribution has a long
right tail (skewness=3.2). The mean gap time (72 hours) and the 75% percentile (50.4 hours)
of subject 1139 are high. The frailty of ID1139 is very low (-0.73). In contrast, consider
ID1328 whose survival curve is shown in figure 2.3. Subject 1328 is a high adherer with a
mean gap time of 24.6 hours. The frailty of ID1328 is 0.25. Frailty estimates can therefore
help characterize the pill-taking behavior of subjects. They can also be useful during the
screening phase of a study. Frailty estimates can help identify poor adherers, and those
subjects are more susceptible to respond to the help of interventionists.
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Figure 2.7: ID 1139's individual survival curve.
Confidence intervals for the random effect can be obtained from a profile likelihood. We
start by computing the likelihood over a range of values for the variance. The 95% profile
likelihood confidence interval is the region where the curve lies above the line, i.e., the set of
values x for which a 1 degree of freedom likelihood ratio test would not reject the hypoth-
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esis that the true standard deviation = x. We get the following estimate of the confidence
interval: from .27 to .35.
0.25 0.30 0.35 0.40
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Standard deviation of the random effect
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* l
og
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Figure 2.8: Profile likelihood for the individual random effect model
We estimate a model containing a random individual effect nested within a random treat-
ment effect. The difference on the likelihood brought about by the treatment effect is very
small and we conclude that the random treatment effect is not statistically significant.
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Table 2.1: Parametric models
Type of model Accelerated Failure Time Frailty model
Baseline hazard No baseline hazard Weibull
Frailty details No frailty gamma
Equation (2.2.1) (2.2.6)
r package survival parfm
Fixed effect parameters Est. (SE) p Est. (SE) p
β male -0.21 (.08) .01 0.18 (0.12) 0.06
β Tstudy - - -0.03 (3.0E-3) < .01
Frailty Parameter
θ - 0.37
Baseline hazard
Parameters
ρ - 1.47
ν - 0.007
Log-likelihood -107133 -96330
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Table 2.2: Frailty models with non parametric baseline hazard
Type of model Fraily model Frailty model
Equation (2.2.5) (2.2.4)
Baseline Nonparametric Nonparametric
hazard
Frailty gamma Gaussian
r package frailtypack coxme
Fixed effect Est. (SE) p Est. (SE) p
Parameters
β male 0.15 (0.08) 0.05 0.15 (0.05) <.01
β Tstudy -0.03 (3.5E-3) <.01 -0.02 (3.4E-3) <.01
Frailty
Parameters
α 0.19 (0.025) -
σ2 - 0.09
Likelihood -228439 -225609
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2.3.5 Model validation
In figure 2.9 we plot the survival functions for the gap times at the beginning and at
the end of the observation period. The gap times at the beginning of the study, when the
participants met with the nurse and the study manager, were shorter than the last gap times.
Figure 2.9: Survival curves of first and last gap times
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2.4 EXPLORATORY CLUSTER ANALYSIS
The goal of this section is to cluster the survival curves of the participants into a small
number of curves representing groups of patients. We use a two-stage approach. In the first
step we reduce the dimension of the survival curves using spline regression. In the second
step we cluster the curves according to the spline coefficients.
2.4.1 Spline regression
We have knots (t1, . . . , tn) and a vector of responses (y1, . . . , yn). We start by considering g
a function consisting of piecewise polynomials. We can put constraints on the behavior of
the function g at the break points.
We can write any function g in the truncated basis power:
g(x) = θ0,1 + θ0,2x+ · · ·+ θ0,kxk−1 +
...
θi,1(x− ti)0+ + θi,2(x− ti)1+ + · · ·+ θi,k(x− ti)k−1+ +
...
θm,1(x− tm)0+ + θm,2(x− tm)1+ + · · ·+ θm,k(x− tm)k−1+
where (·)+ = max(·, 0).
(x − ti)+ is sometimes called a hinge function. (x − ti)k−1+ is a shifted power function
that is truncated to the left of ti.
2.4.1.1 Cubic splines Cubic splines are continuous and have continuous first and second
derivatives. In this case we can write:
g(x) = θ0,1 + θ0,2x+ · · ·+ θ0,4x3 + θ1,k(x− t1)3 + · · ·+ θm,k(x− tm)3
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2.4.1.2 Natural smoothing splines Natural splines add the constraint that the func-
tion must be linear after the knots at the end points. This forces two more restrictions
since g′′ must be 0 at the end points. Among all functions g with two continuous first two
derivatives, find one that minimizes the penalized residual sum of squares
n∑
i=1
{yi − g(ti)}2 + λ
∫ b
a
{g′′(t)}2 dt
where λ is a fixed constant, and a ≤ t1 ≤ · · · ≤ tn ≤ b.
2.4.2 Application to the ACT/CARE study dataset
2.4.2.1 Clustering using ID-level summary measure This approach is simple to
implement and its results can be compared to other clustering methods. Given a set of
observations (x1, x2, . . . , xn), where each observation is a d-dimensional real vector, k-means
clustering aims to partition the n observations into k (≤ n) sets S = {S1, S2, . . . , Sk} so as
to minimize the within-cluster sum of squares (WCSS). In other words, its objective is to
find:
arg min
S
k∑
i=1
∑
x∈Si
‖x− µi‖2
where µi is the mean of points in Si.
The percentage of gap times that lie between 21 and 27 hours are calculated. Also
computed are the percentage of gap times that were greater than 27 hours. Using k-means
Clustering analysis on those two ID-level summary measures, and having indicated 4 clus-
ters, we get the following plot.
The participants of the blue group (about 6%) are low adherers: the prescription bottle
openings in this group are not very frequent when compared to the openings of the other
three groups of participants. The patients seem to have a hard time taking their medication
at the same time of the day: the survival curve drops around 24 and 48 hours are very small.
There does not seem to be a time pattern when it comes to the openings. Those happen at
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many different times in the first 48 hours. About one third of the gap times are longer than
96 hours (or 4 days), when the recommended gap time is 24 hours.
The participants of the purple group (about 36% of the total sample) are high adherers:
the gap times are rarely greater than 24 hours. The patients seem to be very apt at taking
their medication at the same time of the day: the survival curve show a large drop around
24 hours.
Figure 2.10: Clusters
2.4.2.2 Functional data clustering We use a two-stage method, which first reduces
the dimension of the survival curves data using regression on a B-spline basis matrix for a
natural cubic spline. B-spline basis matrices for a polynomial or a restricted cubic spline
are also available. The second stage performs clustering using an approach dedicated to
high-dimensional data (package funHDDC).
Summary descriptives for the resulting cluster curves are presented in table 2.3. The
analysis clustered poor adherers separately from the rest of the participants.
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Figure 2.11: Individual survival curve with spline
Table 2.3: Descriptive statistics of clusters
Cluster number N Pct of gap times
lying between 21
and 27 hours
Pct female Mean age
% % years
1 103 49.9 39.8 46
2 21 31.0 76.2 44
3 51 75.4 49.0 48
4 1 0 100 39
2.5 CONCLUSION AND FUTURE WORK
In this second part of the thesis, we focused on the modeling of medication bottle opening
data. We reviewed several models, and largely focused on frailty models. These models
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provide an important framework for adherence analyses. In chapter 2.2, we focused on
models where the clustering within individuals is accounted for by a gamma or a lognormal
variable. We discussed the interpretation of the random effect of a subject, and how it can
help characterize the adherence of that individual relative to that of the other subjects. In
chapter 2.3, we analyzed a prescription bottle opening data set. We showed that gap time
frailty models can be utilized to identify poor adherers. We evaluated the effects of several
covariates on the gap times, and found gender to be a statistically significant predictor. We
also uncovered a time effect. In chapter 2.4, we clustered the survival curves of the partici-
pants into a small number of curves representing groups of patients. The exploratory cluster
analysis focuses on the shape of the survival curves, and is useful to identify and quantify
different pill-taking behaviors.
In future work, we will apply frailty models to more prescription bottle opening events
data sets. In many adherence studies, different subjects are on different drug regimens, such
as once, twice, three times per day, or every other day, rendering the analysis of data sets
more challenging. Furthermore, we will assess the effects of more predictors on the times
between the administration of doses. Possible predictors of adherence can include sociodemo-
graphic variables, number of comorbidities, mood (anxiety, depression), perceived adherence
(self- reported adherence), and the perception of illness. Other predictors such as economic
hardship and symptom distress could also be investigated. Developing such models will be
very useful for understanding how patient-related and medication-related variables affect
individual adherence.
One limitation of the current approach is that the frailty models we considered use a
proportional hazards transformation. The proportional hazard assumption may not hold for
some covariates. Therefore, implementing a more flexible class of link functions would be
very useful.
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